advertisement
Abstract #27439 Published in IGR 12-4
Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle glaucoma-a pilot study
Yuan H; Yu M; Yang Y; Wu K; Lin X; Li JJournal of Ocular Pharmacology and Therapeutics 2010; 26: 497-501
Objectives: We aimed to investigate whether CYP2D6 polymorphisms were associated with the intraocular pressure (IOP)-lowering effect and systemic complications (especially bradycardia) of ophthalmic timolol. Methods: One hundred twenty-three primary open-angle glaucoma subjects (123 eyes) were treated with 0.5% aqueous formulations of ophthalmic timolol. IOP and heart rate were measured before and after timolol administration. DNA was extracted from venous leukocytes of all the subjects. Two single-nucleotide polymorphisms (SNPs) of CYP2D6, for example, rs16947 (2850C>T, R296C) and rs1135840 (4180C>G, S486T), were detected by restriction fragment length polymorphism analysis. Results: Neither rs16947 (P=0.339) nor rs1135840 (P=0.903) genotype was statistically correlated with the IOP-lowering effect of timolol eye drops. The rs16947 genotype was significantly associated with occurrence of bradycardia in primary open-angle glaucoma patients (P=0.021). The patients with rs16947 CT (P=0.043) or TT (P=0.043) were more inclined to bradycardia than those with rs16947 CC, although there was no significant difference between CT and TT (P=0.177). The analysis of variance showed no significant difference in heart rate (P=0.559) among GG, GC, and CC groups. Conclusions: CYP2D6 SNP rs16947 may confer susceptibility to timolol-induced bradycardia. Patients with CC genotype were unlikely to suffer from timolol-induced bradycardia, whereas those with TT genotype were found to suffer from timolol-induced bradycardia. (copyright) Copyright 2010, Mary Ann Liebert, Inc.
M. Yu. Department of Glaucoma, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou 510060, China. max-yu@tom.com
Classification:
3.4.2 Gene studies (Part of: 3 Laboratory methods > 3.4 Molecular genetics)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
